Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Cisplatin for Malignant Serous Effusions
NCT07090525Phase 2Recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab (2 arms), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Overall Response Rate at 4 weeks. Started Jul 2025; status: recruiting.
02
Drugs
bevacizumab
Beyond the preview
Go deeper on NCT07090525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090525.